Alnylam Pharmaceuticals Inc

ALNY: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$691.00HpkcmhwNfhwdmfzg

Alnylam Earnings: Strong Demand for Amvuttra Drives Sales; Shares Undervalued

Alnylam reported solid third-quarter results highlighted by $313 million in net product revenue, representing a 35% year-over-year increase. Alnylam’s results are largely tracking our expectations, and we maintain our fair value estimate of $199 per share. We view shares as undervalued, currently trading about 15% below our fair value estimate.

Sponsor Center